

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC., and AUSPECT PHARMACEUTICALS, INC., Plaintiffs, v. LUPIN LTD., and LUPIN PHARMACEUTICALS, INC. Defendants.	Civil Action No. 21-cv-13247-FLW-DEA Scheduling Conference: October 19, 2021
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC., and AUSPECT PHARMACEUTICALS, INC., Plaintiffs, v. AUROBINDO PHARMA LTD., and AUROBINDO PHARMA USA, INC. Defendants.	Civil Action No. 21-cv-13240-FLW-DEA Scheduling Conference: October 19, 2021

JOINT PROPOSED DISCOVERY PLAN

Pursuant to Federal Rule of Civil Procedure 26(f), Local Civil Rules 16.1 and 26.1, and the Court’s September 20, 2021 Order (ECF No. 26) (in 21-cv-13247, “the Lupin Case”) and September 28, 2021 Order (ECF No. 24) (in 21-cv-13240, “the Aurobindo Case”), Plaintiffs Teva Branded Pharmaceutical Products R&D, Inc. and Auspex Pharmaceuticals, Inc. (“Auspex”) (collectively, “Plaintiffs” or “Teva”) and Defendants Lupin Ltd. and Lupin Pharmaceuticals, Inc. (collectively, “Lupin”) and Defendants Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc. (collectively, “Aurobindo”) (together with Lupin, “Defendants”), submit the following proposed Joint Discovery Plan and proposed joint scheduling order in the above-captioned matters.

As a preliminary matter, the parties have proposed to coordinate these cases because they are both Hatch-Waxman patent litigations involving Teva's drug AUSTEDO® (deutetrabenazine). AUSTEDO® is indicated for use in treating chorea associated with Huntington's disease and tardive dyskinesia. Both Lupin and Aurobindo have filed Abbreviated New Drug Applications ("ANDAs") seeking approval from FDA to market and sell in the United States the products described therein.

The Aurobindo Case arises from its request to FDA to approve its ANDA prior to the expiry of six U.S. Patents (collectively, the "Asserted Patents"):

- U.S. Patent No. 8,524,733, which includes claims relating to the deutetrabenazine molecule (the "Drug Patent");
- U.S. Patent Nos. 9,233,959, 9,296,739, and 9,814,708, which include claims relating to the dosage form (the "Formulation Patents");
- U.S. Patent No. 9,550,780, which include claims relating to the deutetrabenazine crystal form (the "Polymorph Patent"); and
- U.S. Patent No. 10,959,996, which includes claims relating to the use of deutetrabenazine (the "Use Patent").

The Lupin Case overlaps in subject matter with the Aurobindo case because it arises from its request to FDA to approve its ANDA prior to the expiry of the Formulation Patents and the Polymorph Patent. Lupin has not asked FDA to approve its ANDA prior to the expiry of the Drug Patent.

1. Attorneys

A. Counsel for Plaintiffs, Teva

The attorneys for Plaintiffs Teva Branded Pharmaceutical Products R&D, Inc. and

Auspex Pharmaceuticals, Inc. are:

Liza M. Walsh
Katelyn O'Reilly
William T. Walsh, Jr.
WALSH PIZZI O'REILLY FALANGA LLP
100 Mulberry Street, 15th Floor
Newark, New Jersey 07102
(973) 757-1100

David I. Berl
Thomas S. Fletcher
Shaun P. Mahaffy
Michaela S. Wilkes Klein
Julie L. Tavares
WILLIAMS & CONNOLLY LLP
725 Twelfth Street, N.W.
Washington, DC 20005
(202) 434-5000

B. Counsel for Defendants in the Lupin Case

James S. Richter
MIDLIGE RICHTER, LLC
645 Martinsville Road
Basking Ridge, New Jersey 07920
(908) 626-0622

Deepro R. Mukerjee
Lance A. Soderstrom
Joseph Janusz
KATTEN MUCHIN ROSENMAN LLP
575 Madison Avenue
New York, New York 10022-2585

Jitendra Malik, PhD
KATTEN MUCHIN ROSENMAN LLP
550 S. Tryon Street, Suite 2900
Charlotte, NC 28202-4213

Christopher B. Ferenc
KATTEN MUCHIN ROSENMAN LLP
2900 K Street NW, Suite 200 Washington, DC 20007

C. Counsel for Defendants in the Aurobindo Case

Karen A. Confoy
Paul W. Kalish
FOX ROTHSCHILD LLP
Princeton Pike Corporate Center
997 Lenox Drive
Lawrenceville, NJ 08648
(609) 844-3033

Timothy H. Kratz
George J. Barry III
KRATZ & BARRY LLP
105 Crown Pointe Parkway, Suite 500
Atlanta, GA 30338
(404) 431-6600

2. Statement of Facts and Legal Issues

The Lupin Case is an action for patent infringement arising out of the filing of an Abbreviated New Drug Application by Lupin seeking approval from FDA to market and sell in the United States the product described therein prior to the expiration of the Formulation and Polymorph Patents.

The Aurobindo Case is an action for patent infringement arising out of the filing of an Abbreviated New Drug Application by Aurobindo seeking approval from FDA to market and sell in the United States the product described therein prior to the expiration of the Drug, Formulation, Polymorph, and Use Patents

Plaintiff Auspex owns the Asserted Patents. Plaintiff Teva licenses the Asserted Patents and holds the New Drug Application (“NDA”) pursuant to which it markets AUSTEDO® in the United States. The subject matter of the Asserted Patents are described above.

There is a statutory stay on FDA’s approval of the Defendants’ ANDAs that is in effect until April 3, 2025.

3. Settlement Discussions

The parties have not engaged in settlement discussions.

4. Rule 26(f) Conference

The parties met pursuant to Fed. R. Civ. P. 26(f) on September 30, 2021.

5. Fed. R. Civ. P. 26(a)(1) Disclosures

The parties have agreed to exchange their initial disclosures on October 19, 2021.

6. Problems with Fed. R. Civ. P. 26(a)(1) Disclosures

The parties do not anticipate any issues with Rule 26(a)(1) disclosures.

7. Third Party Funding

The parties have not filed disclosures of third-party litigation funding as they have nothing to disclose.

8. Status of Discovery

The parties have not conducted discovery, with the exception that pursuant to Local Patent Rule 3.6(a) on August 2, 2021, Lupin produced its ANDA No. 216065 to Teva, and on October 11, 2021, Aurobindo produced its ANDA No. 215971 to Teva.

9. Proposed Joint Discovery Plan

A. Discovery Needed on the Following Subjects

The parties expect to take discovery on issues raised in Plaintiffs' Complaints and in any Defendant's Answer, Affirmative Defenses and Counterclaims, which could include a need for physical samples and/or discovery from third parties who may be located abroad.

The Lupin case does not involve the Drug Patent or the Use Patent because Lupin has not sought FDA approval to market its product prior to the expiry of those patents. However, the Aurobindo Case does involve those patents and so the scope of discovery outlined below contemplates discovery concerning those patents.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.